SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Infinity Pharmaceuticals Inc. Reports Phase 1 Data for IPI-145 at American College of Rheumatology/ARHP Supporting Development in Inflammatory Conditions